ProCE Banner Activity

A Metabolic Approach to NASH Management: Emerging Therapies for NASH

Slideset

In this downloadable slideset, learn about emerging metabolic therapies for the management of patients with NASH.

Released: July 28, 2023

Share

Faculty

Stephen Harrison

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Brent A. Tetri

Brent A. Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
St. Louis University School of Medicine
St. Louis, Missouri

Provided by

Jointly provided by the Potomac Center for Medical Education and Rockpointe, in partnership with Clinical Care Options, LLC

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Stephen A. Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC: researcher: Akero, Axcella Health, Cirius, CiVi Biopharma, Cymabay, Enyo Pharma SA, Galectin, Galmed Research & Development, Genfit Corp, Gilead Sciences, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, Poxel, Sagimet Biosciences, Viking; consultant/advisor: 89Bio, AgomAB, Akero, Alentis Therapeutics AG, Altimmune, Arrowhead, Axcella Health, Boston Pharmaceuticals, B Riley FBR, BVF Partners LP, Canfite, Chronwell, CiVi, Corcept, Cymabay, Echosens North America, Enyo Pharma, Fibronostics, Foresite Labs, Fortress Biotech, Galectin, Galmed Research, Genfit Corp, Gilead Sciences, GNS, Hepion, Hightide Therapeutics, HistoIndex PTE LTD, Indalo, Inipharm, Intercept, Ionis, Kowa Research Institute, Madrigal, Medpace, Metacrine, Microba, NGM Biopharmaceuticals, Northsea Therapeutics, Novo Nordisk, Nutrasource, PathAi, Perspectum Diagnostics, Piper Sandler, Poxer, Prometic Pharma, Ridgeline, Sagimet, Sonic Incytes Medical Corp, Terns, Viking Therapeutics; stock/stock options: Akero Therapeutics, Chronwell, Cirius Therapeutics, Galectin Therapeutics, Genfit Corp, Hepion, HistoIndex, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics B.V, Sonic Incytes Medical Corp.

Brent A. Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
St. Louis University School of Medicine
St. Louis, Missouri

Brent Tetri, MD: consultant/advisor: 89Bio, Akero, Arrowhead, Boehringer Ingelheim, Bristol Myers Squibb, Durect, GlaxoSmithKline, Glympse, Hepeon, High Tide, HistoIndex, Labcorp, LG Chem, Madrigal, Merck, Sagimet, Senseion, Target RWE; stock/stock options: HepGene, HeptaBio; researcher (paid to institution): Bristol Myers Squibb, HighTide, Intercept, Inventiva, Madrigal.